Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

[1]  Nicholas Navin,et al.  Tumor evolution: Linear, branching, neutral or punctuated? , 2017, Biochimica et biophysica acta. Reviews on cancer.

[2]  W. Weichert,et al.  Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. de Bree,et al.  Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer , 2016, Oncotarget.

[4]  R. Greil,et al.  Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones , 2016, Oncotarget.

[5]  Lei Chen,et al.  Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer , 2016, OncoTargets and therapy.

[6]  Andrew P. Feinberg,et al.  Epigenetic modulators, modifiers and mediators in cancer aetiology and progression , 2016, Nature Reviews Genetics.

[7]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[8]  Simion I. Chiosea,et al.  Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. , 2016, The Journal of clinical investigation.

[9]  M. Poljak,et al.  Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983–2009: role of human papillomavirus infection , 2015, European Archives of Oto-Rhino-Laryngology.

[10]  M. Schaapveld,et al.  The epidemiology of head and neck squamous cell carcinoma in The Netherlands during the era of HPV-related oropharyngeal squamous cell carcinoma. Is there really evidence for a change? , 2015, Oral oncology.

[11]  Robert Kridel,et al.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.

[12]  R. Yelensky,et al.  Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[14]  R. Greil,et al.  Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma , 2014 .

[15]  A. Psyrri,et al.  The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Silvio Gutkind,et al.  The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies , 2014, Oncotarget.

[17]  David Piwnica-Worms,et al.  Contribution of p53 to metastasis. , 2014, Cancer discovery.

[18]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[19]  M. Brattain,et al.  Cell survival and metastasis regulation by Akt signaling in colorectal cancer. , 2013, Cellular signalling.

[20]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[21]  N. Harris,et al.  A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. , 2012, Blood.

[22]  R. Gibbs,et al.  Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.

[23]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[24]  Chu Chen,et al.  DNA copy number variation and loss of heterozygosity in relation to recurrence of and survival from head and neck squamous cell carcinoma: A review , 2008, Head & neck.

[25]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[26]  M. Karamouzis,et al.  Head and neck cancer , 2008, The Lancet.

[27]  Levi Garraway,et al.  SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines , 2008, Nucleic acids research.

[28]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[29]  Spiros Manolidis,et al.  PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma , 2006, Clinical Cancer Research.

[30]  Dietmar Labeit,et al.  The Complete Gene Sequence of Titin, Expression of an Unusual ≈700-kDa Titin Isoform, and Its Interaction With Obscurin Identify a Novel Z-Line to I-Band Linking System , 2001 .

[31]  S. Gollin.  Chromosomal alterations in squamous cell carcinomas of the head and neck: Window to the biology of disease , 2001, Head & neck.

[32]  C. Machado,et al.  D-Titin , 2000, The Journal of cell biology.

[33]  J. Schlessinger,et al.  Activation of phospholipase Cγ by PI 3‐kinase‐induced PH domain‐mediated membrane targeting , 1998 .

[34]  Subramanian Venkatesan,et al.  Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.